Gastrointestinal perforation during treatment with erlotinib plus bevacizumab in two patients with non-small cell lung cancer exhibiting epidermal growth factor receptor mutations: A case report.
Sign Up to like & getrecommendations! Published in 2018 at "Oncology letters"
DOI: 10.3892/ol.2018.8708
Abstract: A previous randomized phase II study in patients with non-small cell lung cancer (NSCLC) identified that combination treatment with erlotinib plus bevacizumab prolonged progression-free survival compared with erlotinib alone. However, combination bevacizumab and erlotinib treatment… read more here.
Keywords: treatment; erlotinib plus; gastrointestinal perforation; plus bevacizumab ... See more keywords